CTOR
insider transactionsCITIUS ONCOLOGY, INC. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
Transactions · 365d
No open-market buys or sells in this period — showing all activity (grants, exercises & gifts).
-
Grant·A
Chief Medical Officer
$0
825.0K sh
Own New
-
Grant·A
Director
$0
300.0K sh
Own New
-
Grant·A
Director
$0
300.0K sh
Own New
-
Grant·A
Director
$0
300.0K sh
Own +1413%
-
Grant·A
Mazur Leonard L KEY
Chief Executive Officer
$0
1.7M sh
Own New
-
Grant·A
Secretary
$0
850.0K sh
Own New
-
Grant·A
Bartushak Jaime KEY
Chief Financial Officer
$0
825.0K sh
Own New
-
Grant·A
Director
$0
300.0K sh
Own New
-
Grant·A
Director
$0
300.0K sh
Own New
-
Grant·A
Director
$0
300.0K sh
Own New
-
Grant·A
Secretary
$0
850.0K sh
Own New
-
Grant·A
Mazur Leonard L KEY
Chief Executive Officer
$0
1.7M sh
Own New
-
Grant·A
Bartushak Jaime KEY
Chief Financial Officer
$0
825.0K sh
Own New
-
Grant·A
Director
$0
300.0K sh
Own New
-
Grant·A
Director
$0
300.0K sh
Own New
-
Grant·A
Director
$0
300.0K sh
Own New
-
Grant·A
Director
$0
300.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
825.0K sh
Own New
-
Grant·A
Director
$0
300.0K sh
Own New
-
Grant·A
Director
$0
300.0K sh
Own +1413%
-
Grant·A
Director
$0
300.0K sh
Own New
-
Grant·A
Director
$0
300.0K sh
Own New
-
Grant·A
Mazur Leonard L KEY
Chief Executive Officer
$0
1.7M sh
Own New
-
Grant·A
Secretary
$0
950.0K sh · 2 lots
Own New
-
Grant·A
Director
$0
300.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
825.0K sh
Own New
-
Grant·A
Director
$0
300.0K sh
Own +1413%
-
Grant·A
Director
$0
300.0K sh
Own New
-
Grant·A
Director
$0
300.0K sh
Own New
-
Grant·A
Bartushak Jaime KEY
Chief Financial Officer
$0
825.0K sh
Own New
-
Other·J
Director
$0
21.2K sh
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 19, 2025 | Czuczman Myron | Grant A | 825.0K | $0 |
| Sep 19, 2025 | Smith Robert Joseph | Grant A | 300.0K | $0 |
| Sep 19, 2025 | MCGRATH DENNIS M | Grant A | 300.0K | $0 |
| Sep 19, 2025 | Mayersohn Joel David | Grant A | 300.0K | $0 |
| Sep 19, 2025 | Mazur Leonard L KEY | Grant A | 1.7M | $0 |
| Sep 19, 2025 | HOLUBIAK MYRON Z | Grant A | 850.0K | $0 |
| Sep 19, 2025 | Bartushak Jaime KEY | Grant A | 825.0K | $0 |
| Sep 19, 2025 | Webb Carol | Grant A | 300.0K | $0 |
| Sep 19, 2025 | Dutia Suren G | Grant A | 300.0K | $0 |
| Sep 19, 2025 | Holuka Eugene Myron | Grant A | 300.0K | $0 |
| Sep 19, 2025 | HOLUBIAK MYRON Z | Grant A | 850.0K | $0 |
| Sep 19, 2025 | Mazur Leonard L KEY | Grant A | 1.7M | $0 |
| Sep 19, 2025 | Bartushak Jaime KEY | Grant A | 825.0K | $0 |
| Sep 19, 2025 | Smith Robert Joseph | Grant A | 300.0K | $0 |
| Sep 19, 2025 | MCGRATH DENNIS M | Grant A | 300.0K | $0 |
| Sep 19, 2025 | Webb Carol | Grant A | 300.0K | $0 |
| Sep 19, 2025 | Dutia Suren G | Grant A | 300.0K | $0 |
| Sep 19, 2025 | Czuczman Myron | Grant A | 825.0K | $0 |
| Sep 19, 2025 | Holuka Eugene Myron | Grant A | 300.0K | $0 |
| Sep 19, 2025 | Mayersohn Joel David | Grant A | 300.0K | $0 |
| Sep 19, 2025 | Webb Carol | Grant A | 300.0K | $0 |
| Sep 19, 2025 | Smith Robert Joseph | Grant A | 300.0K | $0 |
| Sep 19, 2025 | Mazur Leonard L KEY | Grant A | 1.7M | $0 |
| Sep 19, 2025 | HOLUBIAK MYRON Z | Grant A | 950.0K2 lots | $0 |
| Sep 19, 2025 | Holuka Eugene Myron | Grant A | 300.0K | $0 |
| Sep 19, 2025 | Czuczman Myron | Grant A | 825.0K | $0 |
| Sep 19, 2025 | Mayersohn Joel David | Grant A | 300.0K | $0 |
| Sep 19, 2025 | Dutia Suren G | Grant A | 300.0K | $0 |
| Sep 19, 2025 | MCGRATH DENNIS M | Grant A | 300.0K | $0 |
| Sep 19, 2025 | Bartushak Jaime KEY | Grant A | 825.0K | $0 |
| Jul 28, 2025 | Mayersohn Joel David | Other J | 21.2K | $0 |
Buy Sell Non-market (grant · exercise · gift)
About CTOR insider trading
This page tracks insider transactions for CITIUS ONCOLOGY, INC. (CTOR) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.